Answers are grounded in this paper and cite their sources.
Pharmacokinetic study reveals high bioavailability and slow elimination of orbifloxacin in crucian carp, suggesting clinical efficacy against susceptible bacterial strains.
The pharmacokinetics of orbifloxacin was studied after a single dose (7.5 mg/kg) of intravenous or intramuscular administration to crucian carp (Carassius auratus) reared in freshwater at 25°C. Plasma samples were collected from six fish per sampling point. Orbifloxacin concentrations were determined by high‐performance liquid chromatography with a 0.02 μg/ml limit of detection, then were subjected to noncompartmental analysis. After intravenous injection, initial concentration of 5.83 μg/ml, apparent elimination rate constant (λz) of 0.039 hr−1, apparent elimination half‐life (T1/2λz) of 17.90 hr, systemic total body clearance (Cl) of 75.47 ml hr−1 kg−1, volume of distribution (Vz) of 1,948.76 ml/kg, and volume of distribution at steady‐state (Vss) of 1,863.97 ml/kg were determined, respectively. While after intramuscular administration, the λz, T1/2λz, mean absorption time (MAT), absorption half‐life (T1/2ka), and bioavailability were determined as 0.027 hr−1, 25.69, 10.26, 7.11 hr, and 96.46%, respectively, while the peak concentration was observed as 3.11 ± 0.06 μg/ml at 2.0 hr. It was shown that orbifloxacin was completely but relatively slowly absorbed, extensively distributed, and slowly eliminated in crucian carp, and an orbifloxacin dosage of 10 mg/kg administered intravenously or intramuscularly would be expected to successfully treat crucian carp infected by strains with MIC values ≤0.5 μg/ml.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: